Class action lawsuits
A lawsuit has been filed against Centene Corporation, a leading healthcare company, and certain of its senior executives for potential violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased
Class action lawsuits
Berger Montague, a prominent law firm specializing in securities class action litigation, is investigating potential securities fraud claims on behalf of investors of CTO Realty Growth, Inc. (NYSE: CTO). The firm's investigation follows the filing of a securities class action lawsuit alleging financial manipulation by CTO, including covering
Class action lawsuits
State Teachers Retirement System of Ohio's (State Teachers) securities-fraud class action against Charles River Laboratories International, Inc. (Charles River) has been reversed by the 1st U.S. Circuit Court of Appeals, which found that State Teachers plausibly alleged that Charles River knowingly misled investors about problems in its
Class action lawsuits
Robbins LLP, a law firm specializing in shareholder rights litigation, is investigating allegations that Lineage, Inc. (LINE) misled investors regarding its initial public offering (IPO) in June 2024. The complaint claims that the registration statement filed by Lineage contained false and misleading information, failing to disclose significant weakening in customer
Class action lawsuits
Stockholders of Novo Nordisk A/S, a healthcare company focused on research, development, manufacturing, and distribution of pharmaceuticals, are being reminded of a class action lawsuit filed on their behalf regarding alleged misrepresentations of revenue and profit growth potential. The complaint, filed between May 7, 2025, and July 28, 2025,
Class action lawsuits
A class action lawsuit has been filed against Altimmune, Inc. (NASDAQ: ALT) on behalf of investors who purchased or acquired the company's securities between August 10, 2023, and June 25, 2025. The lawsuit alleges that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial,
Class action lawsuits
Investors in Lineage, Inc. are being notified of a class action securities lawsuit alleging securities fraud. The lawsuit claims that the company made false statements and concealed weaknesses in customer demand, pricing, and operational efficiencies. As a result, Lineage's financial results and business operations were allegedly impaired. The
Class action lawsuits
Investors who purchased Hims & Hers Health, Inc. securities between April 29, 2025, and June 23, 2025, are reminded of the upcoming deadline to file a lead plaintiff motion in the class action lawsuit. The lawsuit alleges that Hims made materially false and/or misleading statements about its business, operations,
Class action lawsuits
Sarepta Therapeutics, Inc.'s investors who bought the company's stock between June 22, 2023, and June 24, 2025, may be eligible to join a class action securities lawsuit. The lawsuit claims that the company and its executives made false statements or concealed the risks associated with ELEVIDYS,
Class action lawsuits
Neogen Corporation, a leading developer of proprietary products for the production and processing of neogen meat and poultry products, finds itself at the center of a securities class action lawsuit. The lawsuit, filed in the United States District Court for the Western District of Michigan, alleges that Neogen and certain
Class action lawsuits
Altimmune investors who were affected by alleged securities fraud between August 10, 2023 and June 25, 2025 may be entitled to compensation. The lawsuit claims that the company failed to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. As
Class action lawsuits
Philadelphia-based law firm Berger Montague PC is investigating claims against Altimmune, Inc. following a class action lawsuit alleging federal securities law violations. Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, may be eligible to seek lead plaintiff representative status. The investigation stems from Altimmune'
